| Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. | |
| | |
MedLine Citation:
|
PMID: 11581004 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND/OBJECTIVE: Pegvisomant is a pegylated analogue of human GH and functions as a potent GH receptor antagonist. This novel mode of action gives it the potential to achieve biochemical control in patients with acromegaly whose disease activity cannot be satisfactorily controlled by conventional therapy. We have documented the clinical details of seven patients with residual active acromegaly after surgery and/or radiation therapy successfully treated with pegvisomant. PATIENTS/METHODS: Seven patients (four male, mean age 47 years, range 34-67 years) who participated in two separate clinical trials of pegvisomant have completed 2 years (four patients) or 1 year (three patients) of treatment. All had active acromegaly (mean serum GH level >5 mU/l; serum IGF-I elevated for age) that could not be controlled with standard medical therapy (dopamine agonist and/or a somatostatin analogue) following appropriate primary treatment with surgery and/or radiotherapy. RESULTS: On a median dose of 20 mg/day (range 15-40) pegvisomant, serum IGF-I fell from a mean of 920+/-351 ng/ml (s.d.) to 258+/-91 ng/ml and was normalised in all seven patients. These changes were associated with improvements in soft tissue enlargement and general well being. Treatment was well tolerated and no change in pituitary tumour size was evident on MRI scans performed every 6 months. CONCLUSIONS: Treatment with pegvisomant is safe and efficacy is maintained after 2 years. Serum IGF-I may be normalised in patients who are refractory to conventional therapy. |
| | |
Authors:
|
W M Drake; C Parkinson; S A Akker; J P Monson; G M Besser; P J Trainer |
Related Documents
:
|
17899104 - Percutaneous treatment of symptomatic non-parasitic benign liver cysts: single-session ... 23159134 - Impact of serum c-reactive protein measurements in the first 2 days on the 30-day morta... 12691394 - Assessment of long-term remission of acromegaly following surgery. 19094074 - Significant tumour shrinkage after 12 months of lanreotide autogel-120 mg treatment giv... 10499384 - Hypnosis with conscious sedation instead of general anaesthesia? applications in cervic... 23049214 - Crohn's disease genotypes of patients in remission vs relapses after infliximab discont... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: 145 ISSN: 0804-4643 ISO Abbreviation: Eur. J. Endocrinol. Publication Date: 2001 Oct |
Date Detail:
|
Created Date: 2001-10-02 Completed Date: 2001-12-04 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 451-6 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology, St Bartholomew's Hospital, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acromegaly
/
drug therapy* Adult Aged Female Human Growth Hormone / adverse effects, analogs & derivatives*, therapeutic use* Humans Insulin-Like Growth Factor I / analysis Male Middle Aged Receptors, Somatotropin / antagonists & inhibitors* Retreatment Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Somatotropin; 0/pegvisomant; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of hydration on exercise-induced growth hormone response.
Next Document: Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women.